John Oyler
John V. Oyler | |
|---|---|
| Born | April 3, 1968 |
| Citizenship | American |
| Alma mater | MIT (BA), Stanford Graduate School of Business (MBA) |
| Occupation | Businessman |
John V. Oyler (born April 03, 1968) is an American businessman, who is a co-founder, chairman, and CEO of BeiGene, a global oncology pharmaceutical company. He is also a board member of the Biotechnology Innovation Organization (BIO).[1][2]
Early life and education
[edit]Oyler was born on April 03, 1968, in Pittsburgh, Pennsylvania. He attended Mt. Lebanon High School, where he first developed his interest in science. While in high school, his scientific research and presentations won awards from Westinghouse in 1985 and 1986, respectively.[3][4]
He holds a bachelor of science in mechanical engineering from Massachusetts Institute of Technology (MIT) and a master of business administration from Stanford Graduate School of Business.[5][1]
Career
[edit]Oyler started his business career while studying at MIT, selling and renting student supplies in the Boston area.[5] After his undergraduate degree, he joined McKinsey & Company, where he served as a consultant while attending Stanford Graduate School of Business.[1]
In 1997, he founded Telephia, which was later sold to Nielsen Co. in 2007. Oyler later launched a contract research organization, BioDuro, in 2005, and it was sold to PPD in 2010.[1][6][7]
Along with Xiaodong Wang, he co-founded BeiGene in 2010 to develop affordable and accessible life-saving oncology medications. Oyler invested $10 million to start BeiGene and secured funding from other angel investors and Merck & Co., becoming its CEO and chairman.[8][9] In 2019, he joined Biotechnical Innovation Organization (BIO) as its board member.[2]
As of 2024, Oyler is serving as the CEO and chairman of BeiGene and a board member of the Biotechnical Innovation Organization (BIO).[1][2][10]
References
[edit]- ^ a b c d e "How — And Why — John Oyler Built BeiGene". www.lifescienceleader.com. Retrieved 2024-09-17.
- ^ a b c "CEO of China health care start-up works hard on cancer drugs pipeline". South China Morning Post. 2017-10-16. Retrieved 2024-09-17.
- ^ "Science winners go to international fair". The Pittsburgh Press. 1986-04-06. p. 33. Retrieved 2024-09-17 – via Newspapers.com.
- ^ "Science". The Pittsburgh Press. 1985-04-03. p. 21. Retrieved 2024-09-17.
- ^ a b "A Vision of Affordability". PharmExec. 2023-03-29. Retrieved 2024-09-17.
- ^ "Drug R&D Heats Up In Beijing". Chemical & Engineering News. Retrieved 2024-09-17.
- ^ Wallace, Claire (2022-10-14). "A new name joins Forbes' growing list of healthcare billionaires". www.beckersasc.com. Retrieved 2024-09-17.
- ^ "BeiGene Brings Biotech to China". Bloomberg.com. 2011-07-07. Retrieved 2024-09-17.
- ^ Bergeron, Tom (2024-07-23). "BeiGene's global goal: Create great medicines — and make them accessible (and affordable) to all". ROI-NJ. Retrieved 2024-09-17.
- ^ Bergeron, Tom (2024-07-23). "BeiGene ribbon-cutting: Big get for life science industry — and bigger vote of confidence for state". ROI-NJ. Retrieved 2024-09-17.
 | This business-related biographical article is a stub. You can help Wikipedia by expanding it. |
 | This article needs additional or more specific categories. (September 2024) |